ENOV 📈 Enovis - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1940145022
ENOV: Orthopedic Braces, Surgical Implants, Therapy Systems, Pain Management Devices
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware. Web URL: https://www.enovis.com
Additional Sources for ENOV Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ENOV Stock Overview
Market Cap in USD | 2,707m |
Sector | Industrials |
Industry | Specialty Industrial Machinery |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2008-05-08 |
ENOV Stock Ratings
Growth 5y | -45.5% |
Fundamental | -46.8% |
Dividend | - |
Rel. Strength Industry | -519 |
Analysts | 4.55/5 |
Fair Price Momentum | 37.04 USD |
Fair Price DCF | 5.91 USD |
ENOV Dividends
No Dividends PaidENOV Growth Ratios
Growth Correlation 3m | 68.4% |
Growth Correlation 12m | -78.6% |
Growth Correlation 5y | -37.4% |
CAGR 5y | -6.96% |
CAGR/Mean DD 5y | -0.24 |
Sharpe Ratio 12m | -0.92 |
Alpha | -62.58 |
Beta | 1.57 |
Volatility | 32.39% |
Current Volume | 1258.4k |
Average Volume 20d | 608k |
What is the price of ENOV stocks?
As of December 21, 2024, the stock is trading at USD 43.12 with a total of 1,258,420 shares traded.
Over the past week, the price has changed by -6.55%, over one month by -3.71%, over three months by -1.26% and over the past year by -21.54%.
As of December 21, 2024, the stock is trading at USD 43.12 with a total of 1,258,420 shares traded.
Over the past week, the price has changed by -6.55%, over one month by -3.71%, over three months by -1.26% and over the past year by -21.54%.
Is Enovis a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Enovis (NYSE:ENOV) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -46.84 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ENOV as of December 2024 is 37.04. This means that ENOV is currently overvalued and has a potential downside of -14.1%.
Probably not. Based on ValueRay Fundamental Analyses, Enovis (NYSE:ENOV) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -46.84 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ENOV as of December 2024 is 37.04. This means that ENOV is currently overvalued and has a potential downside of -14.1%.
Is ENOV a buy, sell or hold?
Enovis has received a consensus analysts rating of 4.55. Therefor, it is recommend to buy ENOV.
Enovis has received a consensus analysts rating of 4.55. Therefor, it is recommend to buy ENOV.
- Strong Buy: 7
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecast for ENOV stock price target?
According to ValueRays Forecast Model, ENOV Enovis will be worth about 40.8 in December 2025. The stock is currently trading at 43.12. This means that the stock has a potential downside of -5.47%.
According to ValueRays Forecast Model, ENOV Enovis will be worth about 40.8 in December 2025. The stock is currently trading at 43.12. This means that the stock has a potential downside of -5.47%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 66.3 | 53.8% |
Analysts Target Price | 70 | 62.3% |
ValueRay Target Price | 40.8 | -5.5% |